Alex Gorsky

Chairman of the Board and Chief Executive Officer, Johnson & Johnson | March 17, 2020

Location: Renaissance Washington, D.C. Downtown Hotel

Time:

6:00 p.m. Registration

7:00 p.m. Luncheon and Program

9:00 p.m.  Adjournment


Alex Gorsky heads a multinational health care corporation with over 250 subsidiary companies and more than 130,000 employees. He is one of just seven leaders to hold dual positions as Chairman of the Board and Chief Executive Officer of Johnson & Johnson since the company was listed on the New York Stock Exchange in 1944. By 2023, Johnson & Johnson is slated to submit applications on ten new drugs and in 2019 gained approval for Spravato, a nasal spray for depression and Balversa, a treatment for bladder cancer. The company is also filing for approval for a newly developed Ebola vaccine, which they plan to donate half a million regimens to the government of the Democratic Republic of the Congo.

Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next three decades, he advanced through positions of increasing responsibility in sales, marketing, and management, culminating in being named Chairman and CEO in 2012.

Related Tags | Health Care